| Issue Date | Title | Author(s) |
| 2023 | Development of quantification methods of a new selective carbonic anhydrase II inhibitor in plasma and blood and study of the pharmacokinetics of its ophthalmic suspension in rats | Khokhlov, A. L.; Yaichkov, I. I.; Korsakov, M. K.; Shetnev, A. A.; Volkhin, N. N. |
| 2024 | Ethical aspects of clinical trials in Russia and BRICS countries: An overview | Simeniv, S. Y.; Khokhlov, A. L.; Soldatova, O. N.; Pyatigorskaya, N. V. |
| 2024 | Identification and synthesis of metabolites of the new 4.5-dihydroisoxazol-5-carboxamide derivate | Khokhlov, A. L.; Yaichkov, I. I.; Alexeev, M. A.; Korsakov, M. K.; Shetnev, A. A. |
| 2024 | Identification and synthesis of metabolites of the new antiglaucoma drug | Khokhlov, A. L.; Yaichkov, I. I.; Korsakov, M. K.; Shetnev, A. A.; Ivanovskiy, S. A. |
| 2018 | Methodical approaches to bioassay of substances containing unstable functional groups | Khokhlov, A. L.; Yaichkov, I. I.; Dzhurko, Yu. A.; Shitov, L. N.; Shitova, A. A. |
| 2020 | Review of bioequivalence studies of cholecalciferol drugs | Khokhlov, A. L.; Romodanovsky, D. P. |
| 2020 | Risk management strategy for preventing the reduced treatment effectiveness from the position of drug interactions and polypharmacy in patients with coronary heart disease | Gruzdeva, A. A.; Khokhlov, A. L.; Ilyin, M. V. |
